Epigenetic therapies for neuroblastoma: immunogenicity awakens
| العنوان: | Epigenetic therapies for neuroblastoma: immunogenicity awakens |
|---|---|
| المؤلفون: | Carlos Jiménez, Lucas Moreno, Miguel F. Segura |
| المساهمون: | Institut Català de la Salut, [Jiménez C] Human Technopole, Milan, Italy. [Moreno L] Grup de Recerca de Càncer i Malalties Hematològiques Infantils, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Segura MF] Grup de Recerca de Càncer i Malalties Hematològiques Infantils, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Wiley, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::Neuroblastoma [DISEASES], Cancer Research, Oncology, Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma [ENFERMEDADES], Otros calificadores::Otros calificadores::/genética [Otros calificadores], terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Other subheadings::Other subheadings::/genetics [Other subheadings], Genetics, Molecular Medicine, Neuroblastoma - Immunoteràpia, General Medicine, Neuroblastoma - Aspectes genètics |
| الوصف: | Immunotherapy; Neuroblastoma Immunoteràpia; Neuroblastoma Inmunoterapia; Neuroblastoma The development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex class I (MHC-I). Cornel et al. showed that epigenetic modulation of neuroblastoma cells with a histone deacetylase inhibitor can boost the expression of major histocompatibility complex class I, among other immune receptors, priming their recognition by T- and natural killer cells. By leveraging the developmentally related aberrant epigenetic landscapes of neuroblastoma, these discoveries pave the way to overcome a major limitation in the field of neuroblastoma immunotherapy. This work was funded by Instituto de Salud Carlos III through the project “PI20/000530” (Co-funded by the European Regional Development Fund/European Social Fund; “A way to make Europe”/“Investing in your future”). |
| وصف الملف: | application/pdf |
| تدمد: | 1878-0261 1574-7891 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a7116ab5c5ad58a26d5905c46a6b0bbTest https://doi.org/10.1002/1878-0261.13404Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1a7116ab5c5ad58a26d5905c46a6b0bb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18780261 15747891 |
|---|